Abstract
Heart failure (HF) is a major cause of morbidity and mortality worldwide. Although many therapeutic means are available to prolong the life of HF patients, why HF develops is still poorly understood. Investigators still seek a truly appropriate animal model that will reliably mimic human HF, so that the cause of the disease can be targeted and proper therapeutic modalities implemented. HF is a complex condition in which multiple molecular mechanisms interact, resulting in compromised cardiac function and often death. Once this elusive animal model is found, investigators will be able to translate findings from the model to human disease, thereby allowing analysis of the molecular changes and dissecting out multiple complicated changes in HF cascade. In this chapter, we describe the methodology that is used to analyze both transcriptional and translational molecular changes and correlate them with cardiac function to assess the cause-and-effect relationship to HF. We used one particular animal model of HF as an example (induced by causing overexpression of myotrophin specifically in the heart) that allowed us to analyze the changes during initiation, progression, and transition of hypertrophy to HF. We have also summarized some other animal models of HF currently available to study mechanisms of HF.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Cleland, J. G., Khand, A., and Clark, A. L. (2001) The HF epidemic: exactly how big is it? Eur. Heart J. 22, 623–626.
Mann, D. L. and Bristow, M. R. (2005) Mechanisms and models in HF: the biomechanical model and beyond. Circulation 111, 2837–2849.
Hoshijima, M. and Chien, K. R. (2002) Mixed signals in HF: cancer rules. J. Clin. Invest. 109, 849–855.
McMurray, J. and Pfeffer, M. A. (2002) New therapeutic options in congestive HF: Part I. Circulation 105, 2099–2106.
McMurray, J. and Pfeffer, M. A. (2002) New therapeutic options in congestive HF: Part II. Circulation 105, 2223–2228.
Dignam, J. D., Martin, P. L., Shastry, B. S., and Roeder, R. G. (1983) Eukaryotic gene transcription with purified components. Methods Enzymol. 101, 582–598.
Iwaki, K., Sukhatme, V. P., Shubeita, H. E., and Chien, K. R. (1990) Alpha-and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an alpha 1-mediated response. J. Biol. Chem. 265, 13,809–13,817.
Tamayo, P., Slonim, D. Mesirov, J., et al. (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc. Natl. Acad. Sci. USA 96, 2907–2912.
Sen, S., Kundu, G., Mekhail, N., Castel, J., Misono, K., and Healy, B. (1990) Myotrophin: purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth. J. Biol. Chem. 265, 16,635–16,643.
Sil, P., Misono, K., and Sen, S. (1993) Myotrophin in human cardiomyopathic heart. Circ. Res. 73, 98–108.
Mukherjee, D. P., McTiernan, C. F., and Sen, S. (1993) Myotrophin induces early response genes and enhances cardiac gene expression. Hypertension 21, 142–148.
Sil, P., Kandaswamy, V., and Sen, S. (1998) Increased protein kinase C activity in myotrophin-induced myocyte growth. Circ. Res. 82, 1173–1188.
Sivasubramanian, N., Adhikary, G., Sil, P. C., and Sen, S. (1996) Cardiac myotrophin exhibits rel/NF-kappa B interacting activity in vitro. J. Biol. Chem. 271, 2812–2816.
Anderson, K. M., Berrebi-Bertrand, I., Kirkpatrick, R. B., et al. (1999) cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy. J. Mol. Cell. Cardiol. 31, 705–719.
Gupta, S. and Sen, S. (2002) Myotrophin-kappaB DNA interaction in the initiation process of cardiac hypertrophy. Biochim. Biophys. Acta 1589, 247–260.
Gupta, S., Purcell, N. H., Lin, A., and Sen, S. (2002) Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J. Cell Biol. 159, 1019–1028.
Adhikary, G., Gupta, S., Sil, P., Saad, Y., and Sen, S. (2005) Characterization and functional significance of myotrophin: a gene with multiple transcripts. Gene 353, 31–40.
Subramaniam, A., Jones, W. K., Gulick, J., Wert, S., Neumann, J., and Robbins, J. (1991) Tissue-specific regulation of the alpha-myosin heavy chain gene promoter in transgenic mice. J. Biol. Chem. 266, 24,613–24,620.
Sarkar, S., Leaman, D. W., Gupta, S., et al. (2004) Cardiac overexpression of myotrophin triggers myocardial hypertrophy and HF in transgenic mice. J. Biol. Chem. 279, 20,422–20,434.
Kubota, T., McTiernan, C. F., Frye, C. S., Demetris, A. J., and Feldman, A. M. (1997) Cardiac-specific overexpression of tumor necrosis factor-alpha causes lethal myocarditis in transgenic mice. J. Card. Fail. 3, 117–124.
Kubota, T., McTiernan, C. F., Frye, C. S., et al. (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81, 627–635.
Nishizuka, Y. (1986) Studies and perspectives of protein kinase C. Science 233, 305–312.
Bowling, N., Walsh, R. A., Song, G., et al. (1999) Increased protein kinase C activity and expression of Ca2+-sensitive isoforms in the failing human heart. Circulation 99, 384–391.
Wakasaki, H., Koya, D., Schoen, F. J., et al. (1997) Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc. Natl. Acad. Sci. USA 94, 9320–9325.
Bowman, J. C., Steinberg, S. F., Jiang, T., Geenen, D. L., Fishman, G. I., and Buttrick, P. M. (1997) Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates. J. Clin. Invest. 100, 2189–2195.
Roman, B. B., Geenen, D. L., Leitges, M., and Buttrick, P. M. (2001) PKC-beta is not necessary for cardiac hypertrophy. Am. J. Physiol. Heart Circ. Physiol. 280, H2264–H2270.
Xuan, Y. T., Tang, X. L., Banerjee, S., et al. (1999) Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits. Circ. Res. 84, 1095–1109.
Morgan, E. N., Boyle, E. M., Jr., Yun, W., et al. (1999) An essential role for NF-kappaB in the cardioadaptive response to ischemia. Ann. Thorac. Surg. 68, 377–382.
Ritchie, M. E. (1998) Nuclear factor-kappaB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 98, 1707–1713.
Wong, S. C., Fukuchi, M., Melnyk, P., Rodger, I., and Giaid, A. (1998) Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive HF. Circulation 98, 100–103.
Groner, F., Rubio, M., Schulte-Euler, P., et al. (2004) Single-channel gating and regulation of human L-type calcium channels in cardiomyocytes of transgenic mice. Biochem. Biophys. Res. Commun. 314, 878–884.
Sato, Y., Ferguson, D. G., Sako, H., et al. (1998) Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J. Biol. Chem. 273, 28,470–28,477.
Jones, L. R., Suzuki, Y. J., Wang, W., et al. (1998) Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J. Clin. Invest. 101, 1385–1393.
Linck, B., Boknik, P., Huke, S., et al. (2000) Functional properties of transgenic mouse hearts overexpressing both calsequestrin and the Na+-Ca2+ exchanger. J. Pharmacol. Exp. Ther. 294, 648–657.
Ito, K., Yan, X., Feng, X., Manning, W. J., Dillmann, W. H., and Lorell, B. H. (2001) Transgenic expression of sarcoplasmic reticulum Ca2+ ATPase modifies the transition from hypertrophy to early HF. Circ. Res. 89, 422–429.
Periasamy, M., Reed, T. D., Liu, L. H., et al. (1999) Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. J. Biol. Chem. 274, 2556–2562.
Schultz Jel, J., Glascock, B. J., Witt, S. A., et al. (2004) Accelerated onset of HF in mice during pressure overload with chronically decreased SERCA2 calcium pump activity. Am. J. Physiol. Heart. Circ. Physiol. 286, H1146–H1153.
Meyer, M., Schillinger, W., Pieske, B., et al. (1995) Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 92, 778–784.
Neumann, J., Boknik, P., DePaoli-Roach, A. A., et al. (1998) Targeted overexpression of phospholamban to mouse atrium depresses Ca2+ transport and contractility. J. Mol. Cell. Cardiol. 30, 1991–2002.
Dash, R., Kadambi, V., Schmidt, A. G., et al. (2001) Interactions between phospholamban and beta-adrenergic drive may lead to cardiomyopathy and early mortality. Circulation 103, 889–896.
Schmitt, J. P., Kamisago, M., Asahi, M., et al. (2003) Dilated cardiomyopathy and HF caused by a mutation in phospholamban. Science 299, 1410–1413.
Crabtree, G. R. (1999) Generic signals and specific outcomes: signaling through calcium2+, calcineurin and NF-AT. Cell 96, 611–614.
Molkentin, J. D., Lu, J. R., Antos, C. L., et al. (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228.
Dong, D., Duan, Y., Guo, J., et al. (2003) Overexpression of calcineurin in mouse causes sudden cardiac death associated with decreased density of K+ hannels. Cardiovasc. Res. 57, 320–332.
Molkentin, J. D. and Dorn, G. W. II. (2001) Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63, 391–426.
Rockman, H. A., Ross, R. S., Harris, A. N., et al. (1991) Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl. Acad. Sci. USA 88, 8277–8281. [Erratum re Fig. 2B is noted in Proc. Natl. Acad. Sci. USA 88, 9907.]
Boluyt, M. O., Robinson, K. G., Meredith, A. L., et al. (2005) Heart failure after long-term supravalvular aortic constriction in rats. Am. J. Hypertens. 18(2 Pt 1), 202–212.
Esposito, G., Rapacciuolo, A., Naga Prasad, S. V., et al. (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105, 85–92.
Carabello, B. A. (1996) Models of volume overload hypertrophy. J. Card. Fail. 2, 55–64.
Scheuermann-Freestone, M., Freestone, N. S., Langenickel, T., Hohnel, K., Dietz, R., and Willenbrock, R. (2001) A new model of congestive HF in the mouse due to chronic volume overload. Eur. J. Heart Fail. 5, 535–543.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc.
About this protocol
Cite this protocol
Gupta, S., Sen, S. (2006). Animal Models for Heart Failure. In: Wang, Q.K. (eds) Cardiovascular Disease. Methods in Molecular Medicine, vol 129. Humana Press. https://doi.org/10.1385/1-59745-213-0:97
Download citation
DOI: https://doi.org/10.1385/1-59745-213-0:97
Publisher Name: Humana Press
Print ISBN: 978-1-58829-892-8
Online ISBN: 978-1-59745-213-7
eBook Packages: Springer Protocols